X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Divestment September 27, 2023
Details:
Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $15.0 million Upfront Cash: $15.0 million
Deal Type: Acquisition July 17, 2023
Details:
Novan intends to use the net proceeds from the offering to fund its SB206 (berdazimer sodium), 10.3% development program activities, support sales and marketing efforts for the Company’s marketed products and for general working capital purposes.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 16, 2023
Details:
Novan intends to use the net proceeds from the offering to fund its SB206 (berdazimer sodium), 10.3% development program activities, support sales and marketing efforts for the Company’s marketed products and for general working capital purposes.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 14, 2023
Details:
SB206 (berdazimer sodium), the active ingredient in berdazimer gel, 10.3% (SB206), is a new chemical entity, for the treatment of molluscum contagiosum is a potential first-in-class topical nitric oxide-releasing agent with positive Phase 3 data submitted to the FDA.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
SB206 (berdazimer sodium), the active ingredient in berdazimer gel, 10.3% (SB206), is a new chemical entity, for the treatment of molluscum contagiosum is a potential first-in-class topical nitric oxide-releasing agent with positive Phase 3 data submitted to the FDA.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ligand Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Dermatology Product Name: Rhofade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $7.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 21, 2022
Details:
WYNZORA Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate used for the topical treatment of plaque psoriasis. Betamethasone dipropionate has anti-inflammatory effects resulting in decreased expression of key TNF-α, IL-17A/F and IL-23 cytokines.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in aqueous formulation.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MC2 Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE 4 in June 2021, achieving statistical significance for primary endpoint with p-value less than 0.0001 and no SAE related to treatment with SB206 (berdazimer) gel, 10.3%.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
